We will soon see. If the P 1BDD trial and P2a are both successful IPIX is imo certain to have tremendous partnership/licensing interest. The reason I felt we could see a great offer sooner is due to efficacy shown in the P2 UP trial coupled with the excellent safety profile shown in the P2 ABSSSI trial. The large potential market , toxic and expensive alternative therapies as well as patients desperate for improved treatments could trigger a big pharma to secure an early deal. Time will tell.

All imo GLTA, Farrell